First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Shapiro Geoffrey I.; Bell-McGuinn Katherine M.; Molina Julian R.; Bendell Johanna; Spicer James; Kwak Eunice L.; Pandya Susan S.; Millham Robert; Borzillo Gary; Pierce Kristen J.; Han Lixin; Houk Brett E.; Gallo Jorge D.; Alsina Maria; Brana Irene; Tabernero Josep

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

【24h】

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

机译：PF-05212384（PKI-587）是晚期癌症患者的小分子，静脉内PI3K和mTOR双重抑制剂的首次人体研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors.

机译：目的：评估晚期实体瘤患者的安全性（主要终点），耐受性，药代动力学，药效学特征和静脉内泛I类同工型PI3K / mTOR抑制剂PF-05212384的初步活性。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2015年第8期|共8页
作者
Shapiro Geoffrey I.; Bell-McGuinn Katherine M.; Molina Julian R.; Bendell Johanna; Spicer James; Kwak Eunice L.; Pandya Susan S.; Millham Robert; Borzillo Gary; Pierce Kristen J.; Han Lixin; Houk Brett E.; Gallo Jorge D.; Alsina Maria; Brana Irene; Tabernero Josep;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer [J] . Shapiro Geoffrey I., Bell-McGuinn Katherine M., Molina Julian R., Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第8期

机译：PF-05212384（PKI-587）是晚期癌症患者的小分子，静脉内PI3K和mTOR双重抑制剂的首次人体研究
2. 387 First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of {PI3K} and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics [J] . G.I. Shapiro, J. Molina, J. Bendell, European Journal of Cancer Supplements . 2010,第7期

机译：[387] PF-05212384是 {PI3K }和mTOR的小分子静脉双重抑制剂在晚期癌症患者中的首次人体研究：关于安全性和药代动力学的初步报告
3. A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors [J] . Wainberg Z., Tabernero J., Maqueda M. A., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：I期研究对雷帕霉素（mTOR）抑制剂PF-05212384与伊立替康联用的双重静脉内（IV）磷脂酰肌醇3-激酶（PI3K）/哺乳动物靶点在患有结直肠癌（CRC）和其他晚期固体的患者（pts）中肿瘤
4. QSAR modeling and structure based virtual screening of new PI3K/mTOR inhibitors as potential anticancer agents [C] . Jelena Oluic, Katarina Nikolic, Mica Vucicevic International Conference on Medical and Biological Engineering . 2017

机译：基于QSAR建模和基于结构的新PI3K / MTOR抑制剂的虚拟筛选潜在抗癌剂
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. First-In-Human Study of PF-05212384 (PKI-587) a Small-Molecule Intravenous Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer [O] . Geoffrey I. Shapiro, Katherine M. Bell-McGuinn, Julian R. Molina, -1

机译：PF-05212384（PKI-587）是晚期癌症患者的小分子静脉注射PI3K和mTOR双重抑制剂的首次人体研究
7. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer [O] . Shapiro, Geoffrey I, Bell-McGuinn, Katherine M, Molina, Julian R, 2015

机译：PF-05212384（PKI-587）是晚期癌症患者的小分子，静脉内PI3K和mTOR双重抑制剂的首次人体研究

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

摘要

著录项

相似文献

相关主题

期刊订阅